Demographic, clinical, and laboratory features of the patients with axSpA (n = 174) in remission and under treatment with TNF-α blockers. The measures of disease activity are the median values of the remission period. Values are median (IQR) or n (%) unless otherwise specified.
| Variables | Values |
|---|---|
| Male/female, n | 133/41 |
| Age, yrs, mean (SD) | 43.2 (12.7) |
| Disease duration, yrs | 7 (3–14) |
| Presence of HLA-B27 | 122 (70.1) |
| CRP, mg/dl | 0.3 (0.1–0.5) |
| ESR, mm/h | 9 (4–13.75) |
| BASDAI | 1.6 (0.9–2.4) |
| BASMI | 2 (0–3) |
| BASFI | 1.5 (0.7–2.4) |
| PtGA, cm | 1.2 (0.5–2) |
| VAS physician, cm | 0.5 (0–1.5) |
| VAS back pain, cm | 1.3 (0.4–2) |
| ASDAS-CRP | 1.1 (0.6–1.5) |
| Presence of grade IV sacroiliitis | 44 (25.2) |
| Presence of psoriasis | 18 (10.3) |
| Presence of IBD | 20 (11.4) |
| Presence of uveitis | 23 (13.1) |
| Therapy | |
| NSAID, continuous | 21 (12.1) |
| sDMARD | 25 (14.3) |
| IFX | 102 (58.6) |
| ADA | 25 (14.3) |
| ETN | 47 (27.1) |
axSpA: axial spondyloarthritis; TNF-α: tumor necrosis factor-α; IQR: interquartile range; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; PtGA: patient’s global assessment; VAS: visual analog scale; ASDAS: Ankylosing Spondylitis Disease Activity Score; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drugs; sDMARD: synthetic disease-modifying antirheumatic drugs; IFX: infliximab; ADA: adalimumab; ETN: etanercept.